Xo1 Limited

xo1 is a virtual biopharmaceutical company developing ichorcumab, an antibody against thrombin that will potentially deliver anticoagulation without bleeding. xo1 was founded in april 2013 by index ventures as an asset-centric development company to bring a single drug candidate, the anti-thrombin antibody ichorcumab, into the clinic, under license from cambridge university. ichorcumab is a synthetic human igg4 based on a naturally-occurring antibody detected in a single patient that conferred complete anticoagulation in the absence of any observed increase in bleeding risk. ichorcumab binds to the exosite 1 region of thrombin, blocking the binding of the key substrate fibrinogen, but does not inhibit the catalytic activity of the protease. xo1 expects to begin clinical trials in 2015, and develop the product candidate for a range of indications where drugs such as warfarin, anti-platelet agents and novel oral anti-coagulants (noacs) are currently used, including venous thromboembolism